GSK plc (GSK), with its development partner iTeos Therapeutics (ITOS), confirmed it is ending the development program for belrestotug, an anti-TIGIT monoclonal antibody. “The decision is based on new interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the established efficacy criteria for continued development. As a result, the collaboration and all belrestotug-containing study cohorts are ending,” GSK stated.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- iTeos: GALAXIES Lung-201 did not meet criteria for meaninful improvements in PFS
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- White House publishes Trump executive order aimed at lowering drug prices
- Trump to sign executive order aimed at lowering drug prices